Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ISRCTN10996483) titled 'Determining the role of synthetic cannabinoids in eye pressure and tolerability measurements' on April 1.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Crossover
Purpose: Treatment
Primary Sponsor: Belfast Health and Social Care Trust
Condition:
Ocular hypertension or early primary open angle glaucoma
Eye Diseases
Intervention:
The investigational medicinal product (IMP) will be ART27.13, a synthetic, peripherally selective cannabinoid which is under development by Artelo Biosciences. The study will run as a cro...